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Abstract
Background—Data from prospective cohort studies regarding the association between
subclinical hyperthyroidism and cardiovascular outcomes are conflicting. We aimed to assess the
risks of total and coronary heart disease (CHD) mortality, CHD events, and atrial fibrillation (AF)
associated with endogenous subclinical hyperthyroidism among all available large prospective
cohorts.
Methods—Individual data on 52 674 participants were pooled from 10 cohorts. Coronary heart
disease events were analyzed in 22 437 participants from 6 cohorts with available data, and
incident AF was analyzed in 8711 participants from 5 cohorts. Euthyroidism was defined as
thyrotropin level between 0.45 and 4.49 mIU/L and endogenous subclinical hyperthyroidism as
thyrotropin level lower than 0.45 mIU/L with normal free thyroxine levels, after excluding those
receiving thyroid-altering medications.
Results—Of 52 674 participants, 2188 (4.2%) had subclinical hyperthyroidism. During follow-
up, 8527 participants died (including 1896 from CHD), 3653 of 22 437 had CHD events, and 785
of 8711 developed AF. In age-and sex-adjusted analyses, subclinical hyperthyroidism was
associated with increased total mortality (hazard ratio [HR], 1.24, 95% CI, 1.06–1.46), CHD
mortality (HR, 1.29; 95% CI, 1.02–1.62), CHD events (HR, 1.21; 95% CI, 0.99–1.46), and AF
(HR, 1.68; 95% CI, 1.16–2.43). Risks did not differ significantly by age, sex, or preexisting
cardiovascular disease and were similar after further adjustment for cardiovascular risk factors,
with attributable risk of 14.5% for total mortality to 41.5% for AF in those with subclinical
hyperthyroidism. Risks for CHD mortality and AF (but not other outcomes) were higher for
thyrotropin level lower than 0.10 mIU/L compared with thyrotropin level between 0.10 and 0.44
mIU/L (for both, P value for trend, ≤.03).
Conclusion—Endogenous subclinical hyperthyroidism is associated with increased risks of
total, CHD mortality, and incident AF, with highest risks of CHD mortality and AF when
thyrotropin level is lower than 0.10 mIU/L.
Subclinical hyperthyroidism, defined by low thyrotropin level with normal concentrations of
free thyroxine (FT4) and triiodothyronine (T3),1–4 has been associated with several
biological effects on cardiovascular system, such as increased heart rate, left ventricular
mass, carotid intimamedia thickness, and plasma fibrinogen levels.3,5 Observational studies
have reported an association between subclinical hyperthyroidism and coronary heart
disease (CHD),6–8 incident atrial fibrillation (AF),9–12 and cardiac dysfunction.13,14 Results
from prospective cohort studies are conflicting,6,10 and study-level meta-analyses have
reached contradictory conclusions, for example, regarding the association between
subclinical hyperthyroidism and cardiovascular mortality.15–17 In fact, interpretation of
these studies is hampered by several methodological factors: population heterogeneity,
different thyrotropin cutoff levels for subclinical hyperthyroidism definition, different use of
covariates, and different CHD definitions.16 Although no large randomized controlled trials
have examined the effects of treating subclinical hyperthyroidism on clinically relevant
outcomes, a consensus statement2 and recent guidelines4 advocate treatment of subclinical
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hyperthyroidism, particularly when thyrotropin level is lower than 0.10 mIU/L, to avoid
long-term complications.
Individual participant data analysis from large cohort studies may help reconcile these
conflicting results; allow exploration of the influence of age, sex, thyrotropin levels, and
preexisting cardiovascular disease (CVD); and allows the use of a uniform thyrotropin
cutoff level and outcome definitions for all participants. This approach is considered optimal
for synthesizing evidence across cohorts because it is not subject to potential bias from
study-level meta-analyses (ecological fallacy)18 and allows performance of time-to-event
analyses.19
On the basis of data from the Thyroid Studies Collaboration,20 we aimed to assess the risks
of total mortality, CHD mortality, CHD events, and AF associated with endogenous
subclinical hyperthyroidism.
METHODS
Similar to our previous study,20 we conducted a systematic literature search in MEDLINE
and EMBASE databases from 1950 to June 30, 2011, without language restriction
(eAppendix; http://www.archinternmed.com), and screened bibliographies from retrieved
articles. We used a priori criteria for greater comparability and quality of the studies. We
included only full-text published longitudinal cohorts reporting baseline thyroid function test
results (both thyrotropin and FT4), with a control euthyroid group and prospective follow-up
of mortality and CHD outcomes. We excluded studies that included only participants taking
thyroid-altering medications (antithyroid drugs, thyroxine, or amiodarone) or participants
with overt hyperthyroidism (low thyrotropin and high FT4 levels). We performed an
additional systematic literature review for articles reporting incident AF events and updated
our previous search20 to June 2011. Reviews were performed independently by 2 authors
(P.B. and B.G.), and discrepancies were resolved by discussion with a third author (N.R.).
Agreement between reviewers was 99.9% for first screen (titles and abstracts, κ=0.66; 95%
CI, 0.62–0.72) and 100% for full-text screen (κ= 1.00).
Data were collected from original studies that joined the Thyroid Studies Collaboration20
and included individual demographic characteristics; thyrotropin, FT4, and total T3 or free
T3 levels; baseline cardiovascular risk factors (eg, blood pressure, cigarette smoking, total
cholesterol level, diabetes mellitus); preexisting CVD; and cardiovascular and thyroid-
altering medication use at baseline and during follow-up. Data on mortality, CHD events,
AF, stroke, and cancer outcomes were requested.
Similar to our previous analysis,20 we used a uniform thyrotropin cutoff level for subclinical
hyperthyroidism definition, based on an expert consensus meeting of our collaboration20
(International Thyroid Conference, Paris, France, 2010), expert reviews,1,21 and previous
large cohorts.10,22,23 Subclinical hyperthyroidism was defined as a thyrotropin level lower
than 0.45 mIU/L with normal FT4 levels, and euthyroidism as a thyrotropin level between
0.45 and 4.49 mIU/L. Subclinical hyperthyroidism was further categorized as suppressed
thyrotropin level (<0.10 mIU/L) and low but not suppressed thyrotropin level (0.10–0.44
mIU/L) according to current guidelines.1,4 Data from cohorts using first-generation
thyrotropin assays (functional sensitivity, 1–2 mIU/L) were excluded9,24,25 because
subclinical hyperthyroidism cannot be diagnosed using these methods.26 For FT4 and total
and free T3, we used study-specific cutoff values because these measurements show greater
intermethod variation than thyrotropin assays. For participants with missing values of FT4
and total or free T3 (measured in 5 of 10 cohorts [eTable]), we performed sensitivity
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analyses excluding (1) participants with missing FT4 values and (2) those with abnormal
total or free T3 levels.1–4,21
Outcomes were total mortality, CHD mortality, CHD events, and incident AF. Stroke and
cancer mortality were available for all cohorts except one.27 As in our previous analysis,20
we used homogenous definitions to reduce the heterogeneity in outcomes.15,16 Similar to the
Framingham risk score,28 we limited cardiovascular mortality to CHD mortality or sudden
death (eTable). We defined CHD events as nonfatal myocardial infarction or CHD death
(equivalent to hard events28) or hospitalization for angina or coronary revascularization.10
We performed a sensitivity analysis with hard CHD events only (ie, CHD death, nonfatal
myocardial infarction). For AF analyses, participants with baseline AF were excluded
(eTable).
To assess the risks of endogenous subclinical hyperthyroidism, we excluded participants
using thyroxine or antithyroid drugs at baseline. To explore the possible heterogeneity
between exogenous (using thyroid-altering medications) and endogenous subclinical
hyperthyroidism, we performed sensitivity analyses by adding participants using thyroxine
or antithyroid drugs at baseline.
We conducted a study quality evaluation using previous criteria16 after collecting the
following additional information from study authors: methods of outcome adjudication and
ascertainment, accounting for confounders, and completeness of follow-up.
The association between subclinical hyperthyroidism and each outcome was analyzed using
separate Cox proportional hazard models for each cohort (SAS 9.2 [SAS Institute Inc]; Stata
11.2 [StataCorp]). Pooled estimates for each outcome were calculated using random-effects
models based on inverse variance model29 as recommended.19,30,31 Results were
summarized using forest plots (Review Manager 5.1.2, Nordic Cochrane Centre). To assess
heterogeneity across studies, we used the I2 statistic, which measures the inconsistency
across studies attributable to heterogeneity instead of chance alone.32
Primary analyses were adjusted for age and sex (some traditional cardiovascular risk factors
being potential mediators3), then further adjusted for traditional cardiovascular risk factors
(systolic blood pressure, current or former smoking, total cholesterol, and diabetes). As
missing data rates were lower than 3% and unlikely to substantially bias the multivariate
model estimates,33 complete case analysis was used.
To explore potential sources of heterogeneity, we performed predefined subgroup and
sensitivity analyses, as in our previous analysis.20 We conducted stratified analyses by age,
sex, race, thyrotropin categories, and preexisting CVD. For strata with participants but no
event in some subgroup analyses, we used penalized likelihood methods34 to calculate
hazard ratios (HRs) and 95% confidence intervals. To calculate age- and sex-adjusted event
rates/1000 person-years, we used Poisson models.35 We checked the proportional hazard
assumption using graphical methods and the Schoenfeld test.36 For publication bias, we used
age- and sex-adjusted funnel plots and the Egger test.37
RESULTS
Among identified reports, 13 prospective cohorts met all inclusion criteria (eFigure). We
excluded 3 cohorts9,24,25 using first-generation thyrotropin assays,26 which were
insufficiently sensitive for the diagnosis of subclinical hyperthyroidism. After the exclusion
of users of thyroxine and antithyroid drugs, the final sample comprised 10 prospective
cohorts with a total of 52 674 participants (median age, 59 years, 58.5% women), with
median follow-up 8.8 years and total follow-up 501 922 persons-years. Of the participants,
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50 486 were euthyroid and 2188 (4.2%) had endogenous subclinical hyperthyroidism (Table
1), including 1884 participants (3.6%) with low but not suppressed thyrotropin (0.10–0.44
mIU/L) and 304 (0.6%) with suppressed thyrotropin (<0.10 mIU/L). The loss to follow-up
rate was lower than 5% in all included studies. Total and CHD mortality were reported in all
cohorts. Coronary heart disease event data were available for 22 437 participants from 6
cohorts (3.2% with subclinical hyperthyroidism), and were formally adjudicated for 4 of
these 6 studies.7,8,10,38 After excluding those with AF at baseline, data for incident AF
events were available in 8711 participants from 5 cohorts (9.3% with subclinical
hyperthyroidism).
During follow-up, 8527 participants died (including 1896 from CHD), 3653 had CHD
events, and 785 had incident AF. In age- and sex-adjusted analyses, the overall HR for
participants with subclinical hyperthyroidism compared with euthyroidism was 1.24 (95%
CI, 1.06–1.46; 23.5 vs 19.9/1000 person-years for euthyroidism) for total mortality, 1.29
(95% CI, 1.02–1.62; 5.1 vs 4.5/ 1000 person-years) for CHD mortality, 1.21 (95% CI, 0.99–
1.46; 24.1 vs 20.9/1000 person-years) for CHD events, and 1.68 (95% CI, 1.16–2.43; 17.1
vs 12.5/1000 person-years) for incident AF (Figure). Stroke and cancer mortality were not
higher with subclinical hyperthyroidism. Heterogeneity was present across studies for total
mortality (I2 = 49%), but not for CHD mortality, CHD events or incident AF (all I2 = 0%).
Among subclinical hyperthyroid and euthyroid groups, there was a trend for more late
events than early events for total mortality, CHD mortality, CHD events, and AF events (for
all, P value for trend, ≤.02). We subsequently examined whether heterogeneity was related
to differences in risks by degree of subclinical hyperthyroidism and age.
Table 2 presents stratified analyses for total mortality, CHD mortality, CHD events, and
incident AF. In age-and sex-adjusted analyses, CHD mortality and incident AF (but not
other outcomes) were significantly greater in participants with lower thyrotropin levels:
HRs, 1.24 (95% CI, 0.96–1.61) and 1.63 (95% CI, 1.10–2.41) for thyrotropin levels 0.10–
0.44 mIU/L, respectively, vs HRs, 1.84 (95% CI, 1.12–3.00) and 2.54 (95% CI, 1.08–5.99)
for thyrotropin levels lower than 0.10 mIU/L, respectively (for both, P value for trend, ≤.03
for each outcome). Men had a slightly greater risk for total mortality, CHD mortality and
incident AF, without statistical significance for interaction (all P ≥ .30). Risks for Asian
participants were greater for total mortality (HR, 2.73; 95% CI, 1.53–4.88) and CHD
mortality (HR, 2.35; 95% CI, 0.50–11.14), with nonsignificant interaction test results (all P
≥ .40), but data on Asian participants were available from only 1 cohort.40 Risks did not
differ significantly by age or preexisting CVD. All risks were similar after further
adjustment for cardiovascular risk factors, with an attributable risk of 14.5% for total
mortality to 41.5% for AF in those with subclinical hyperthyroidism and a population
attributable risk of 0.7% for total mortality to 6.2% for AF, given the relatively low
prevalence of subclinical hyperthyroidism.
Sensitivity analyses yielded similar results (Table 3). Excluding users of thyroxine and
antithyroid drugs during follow-up or adding participants taking these medications at
baseline to the overall sample yielded similar HRs. The risk of CHD mortality was higher
(HR, 1.50; 95% CI, 1.00–2.27) after limiting the analyses to 4 studies with formal
adjudication procedures.7,8,13,38 Risks of total mortality, CHD mortality and incident AF
increased slightly after excluding a study with previous iodine supplementation.39 Risks
were similar after further adjustment of multivariate models with lipid-lowering and
antihypertensive medication use or body mass index.
The proportional hazard assumption was consistent across studies, except for the
Birmingham Study6 (P = .009), which was excluded in a sensitivity analysis giving similar
results. We found limited evidence of publication bias with visual assessment of age- and
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sex-adjusted funnel plots and the Egger test for total mortality (P = .17), but not the other
outcomes (all P ≥ .20). For total mortality, the Brazilian Thyroid Study40 might be an outlier
with no corresponding study of similar size with reduced risk associated with subclinical
hyperthyroidism: a sensitivity analysis excluding this study yielded similar results.
COMMENT
In this analysis of all available prospective cohorts, endogenous subclinical hyperthyroidism
was associated with an increased risk of total mortality, CHD mortality, and incident AF.
Coronary heart disease mortality and incident AF (but not other outcomes) were
significantly greater in participants with thyrotropin levels lower than 0.10 mIU/L than those
with thyrotropin levels between 0.10 and 0.44 mIU/L (for both, P value for trend, ≤.03).
Risks did not differ significantly by age, sex, or preexisting CVD and were similar after
further adjustment for cardiovascular risk factors.
Previous study-level meta-analyses produced conflicting results regarding the association
between subclinical hyperthyroidism and cardiovascular mortality.15–17 Our results, based
on individual participant data, demonstrate that there is indeed an increased risk of total and
CHD mortality associated with subclinical hyperthyroidism,15,16 and add new information
on subgroups at increased risk and the risk of incident AF. Previous meta-analyses could not
accurately assess the differences in risk according to thyrotropin level, because of potential
ecological fallacy without individual participant data analysis18 and they pooled individual
studies using varying thyrotropin cutoff levels, outcome definitions, and confounding factors
for adjustment.15,16 Only a few individual studies reported stratified risks according to
thyrotropin levels. Our results are consistent with those recently reported by Vadiveloo et
al,41 who found an increased risk of nonfatal CVD, increasing with lower thyrotropin levels
(HR, 1.67 [95% CI, 1.45–1.92] for thyrotropin level 0.10–0.40 mIU/L, vs HR, 1.74 [95%
CI, 1.36–2.21] for thyrotropin level <0.10 mIU/L); this study was not included in our
analysis because of its retrospective case-control design.
To our knowledge, no meta-analysis has been conducted on the association of AF with
subclinical hyperthyroidism. Similar to our data, some individual studies showed increased
risk of AF associated with subclinical hyperthyroidism.9,10 Sawin et al9 reported an
increased risk of incident AF in persons older than 60 years with thyrotropin levels lower
than 0.1 mIU/L (HR, 3.8; 95% CI, 1.7–8.3) and among those with thyrotropin levels
between 0.1 and 0.4 mIU/L (HR, 1.6; 95% CI, 1.0–2.5); this study was excluded from our
analysis because of its first-generation thyrotropin assay.26 Cappola et al10 showed a
relationship between low thyrotropin levels and AF incidence in individuals 65 years or
older with endogenous subclinical hyperthyroidism, which was also significant in those with
thyrotropin levels between 0.10 and 0.44 mIU/L (HR, 1.85; 95% CI, 1.14–3.00). In a
population with a mean age of 65.5 years, Vadiveloo et al41 found an increased risk of
cardiac arrhythmia for participants with endogenous subclinical hyperthyroidism, especially
in those with thyrotropin levels lower than 0.10 mIU/L. Taken together, these previous
studies and our data suggest that the risk of AF in individuals with endogenous subclinical
hyperthyroidism is higher with lower thyrotropin levels and is mostly pronounced in those
with thyrotropin levels lower than 0.10 mIU/L.
The increased risks of AF events and total and CHD mortality associated with subclinical
hyperthyroidism have been postulated to be caused by systemic effects of thyroid hormones,
such as a change in cardiac function1,3 or cardiac arrhythmia.3,42 These hypotheses are
favored by the fact that adjustment for cardiovascular risk factors did not alter risks of
subclinical hyperthyroidism. An alternative explanation for the results could be publication
bias, selection bias or quality issues in the included cohorts, or unmeasured confounders.43
Collet et al. Page 6
Arch Intern Med. Author manuscript; available in PMC 2013 December 25.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Sensitivity analyses (1) excluding a small study40 with no corresponding study of similar
size with reduced risk associated with subclinical hyperthyroidism and (2) pooling only
higher-quality cohorts yielded similar results.
Among the strengths of our study, an individual participant data analysis is considered the
best way for synthesizing evidence across several studies because it is not subject to
potential bias from study-level meta-analyses (ecological fallacy)18 and allows performance
of time-to-event analyses and use of standardized definitions of predictors, outcomes, and
adjustment for confounding factors.19 We included all available international published data
after conducting a systematic review.
Among the limitations of our study, our analysis included predominantly white populations,
except for one cohort including Brazilians of Japanese descent.40 Although we included all
available data, our results may not be generalized to all other populations. Second, thyroid
function tests were performed only at baseline, and we have no data to assess how many
participants with subclinical hyperthyroidism progressed to overt hyperthyroidism or
normalized to euthyroidism over time, which is a limitation of most published large
cohorts.10,23,27,38 Third, subclinical hyperthyroidism was defined as a thyrotropin level
lower than 0.45 mIU/L and normal FT4 levels, since T3 was not measured in all included
cohorts; sensitivity analyses excluding participants with abnormal total or free T3 levels
yielded similar results. Fourth, the high prevalence of subclinical hyperthyroidism in the
Study of Health in Pomerania (SHIP, Northern Germany, 24.1%) may be explained by the
iodine supplementation that was introduced in the area 4 years before the start of SHIP in
the late 1990s.44 Excluding SHIP yielded similar risk estimates. Fifth, we did not have
information on the etiology of subclinical hyperthyroidism, while cardiovascular
complications may be related to the etiology of the condition.45 Sixth, up to 2.6% of
participants started thyroxine or antithyroid drugs during follow-up; sensitivity analyses
excluding users of these medications during follow-up yielded similar results. However, we
did not have complete data from all cohorts on use of other medications that could alter
thyrotropin and/or FT4 levels, such as steroids or amiodarone; sensitivity analyses excluding
other medications users (0%–2.8% when available) yielded similar results. Seventh, only
mortality and cardiovascular outcomes were assessed. Other conditions such as osteoporosis
and cognition were not analyzed and could partly account for increased total mortality,
particularly among elderly persons, although data on the associations between subclinical
hyperthyroidism and osteoporosis and cognition are conflicting.1 Eighth, 4 of 6
studies7,8,10,38 formally adjudicated CHD outcomes. Sensitivity analyses limited to these 4
studies yielded similar risk estimates. As most included cohorts used self-reported
preexisting CVD, stratified analyses according to preexisting CVD should be interpreted
with caution.
Recent guidelines4 recommend that “treatment of SH [subclinical hyperthyroidism] should
be strongly considered in all individuals ≥65 years of age” with thyrotropin level lower than
0.10 mIU/L (recommendation 65) and “treatment of SH should be considered in individuals
≥65 years of age” with low thyrotropin levels but 0.1 mIU/L or higher (recommendation
66). Based on all available prospective cohort studies, our findings of increased risks of total
mortality, CHD mortality, and incident AF associated with subclinical hyperthyroidism,
with greater risks of CHD mortality and AF among those with thyrotropin levels lower than
0.10 mIU/L, are consistent with these recent guidelines.4 However, findings based on
observational data should be interpreted with great caution for clinical practice, since they
are subject to several aforementioned limitations. No clinical trials have assessed whether
treating subclinical hyperthyroidism results in improved cardiovascular outcomes. Because
our data included only a limited sample of young men and premenopausal women,
generalization of our findings to younger adults is limited.
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In conclusion, pooling individual data from all available prospective cohorts suggests that
endogenous subclinical hyperthyroidism is associated with an increased risk of total
mortality, CHD mortality, and incident AF, with higher risks of CHD mortality and AF with
thyrotropin levels below 0.10 mIU/L. Our study is observational, and as such cannot address
whether the risks associated with subclinical hyperthyroidism are lowered by treatment. A
large randomized controlled trial with relevant clinical outcomes will be required to
demonstrate whether these risks are altered by therapy; such a trial will be challenging to
conduct given the large sample size required and the lower prevalence of adults with
subclinical hyperthyroidism compared with subclinical hypothyroidism. If conducted, such a
trial should examine prevention of AF and surrogate outcome measures, such as carotid
intimamedia thickness.46
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Figure.
Total mortality, coronary heart disease (CHD) mortality, CHD events, and atrial fibrillation
in endogenous subclinical hyperthyroidism vs euthyroidism. Age and sex-adjusted hazard
ratios (HRs) and their 95% confidence intervals (CIs) are represented by squares or
diamonds, those to the right of the solid line indicate increased risk. The sizes of data
markers are proportional to the inverse of the variance of the HRs. *Forty-one participants
were excluded from the analyses of CHD mortality because of missing cause of death. †The
Birmingham Study,6 HUNT (Nord-Trøndelag Health Study),27 SHIP (Study of Health in
Pomerania),39 and Brazilian Thyroid Study40 were not included because follow-up data
were only available for death. EPIC indicates European Prospective Investigation of Cancer.
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